SUPPLEMENTARY MATERIALS

Systematic Review of Myelitis in COVID-19

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Year** | **Newcastle-Ottawa Scale** |  |  |   |   |   |   |
|  |  | **Selection** |  |  | **Comparability** | **Outcome** |  |  | **Total** |
|  |  | **Representativeness** | **Selection** | **Exposure ascertainment** | **Outcome not present at beginning** |  | **Assessment** | **Follow-up length** | **Follow-up quality** |   |
| Abdelhady(1) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| AlKetbi(2) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Baghbanian(3) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Chakraborty(4) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Chow(5) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Durrani(6) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Giorgianni(7) | 2020 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Kaur(8) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Lisnic(9) | 2020 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Maideniuc(10) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Masuccio(11) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Munz(12) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Paterson(13) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Rifino(14) | 2020 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 6 |
| Rifino(14) | 2020 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 6 |
| Sarma(15) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Sotoca(16) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Valiuddin(17) | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Wong(18)  | 2020 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Zachariadis(19) | 2020 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Zhao(20) | 2020 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |

Supplementary Table 1: Bias assessment using the Newcastle-Ottawa Scale.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Blood laboratory findings** |  |  |  |  |  |  |  |  |  |  |
|  | **WBC** | **lymphocytes** | **platelets** | **Hb** | **ESR** | **ALAT/ASAT** | **D-dimers** | **aPTT** | **CRP** | **PCT** | **CK** | **creatinine** |
| Abdelhady(1) | + | + | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| AlKetbi(2) | WNL | NA | NA | - | WNL | NA | + | + | + | + | + | NA |
| Baghbanian(3) | WNL | NA | NA | NA | WNL | WNL | NA | NA | WNL | NA | NA | NA |
| Chakraborty(4) | WNL | WNL | WNL | WNL | WNL | WNL | NA | NA | NA | NA | NA | WNL |
| Chow(5) | WNL | WNL | (+) | WNL | + | WNL | + | NA | + | NA | WNL | WNL |
| Durrani(6) | WNL | WNL | WNL | WNL | WNL | WNL | NA | NA | WNL | NA | NA | WNL |
| Giorgianni(7) | + | - | WNL | NA | NA | + | + | NA | + | NA | NA | - |
| Kaur(8) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Lisnic(9) | + | NA | NA | NA | NA | NA | NA | NA | WNL | NA | NA | NA |
| Maideniuc(10)\* Valiuddin(17)\* | + | WNL | WNL | WNL | NA | WNL | WNL | NA | WNL | WNL | WNL | WNL |
| Masuccio(11) | WNL | - | WNL | WNL | NA | WNL | NA | NA | + | NA | WNL | WNL |
| Munz(12) | WNL | NA | WNL | WNL | NA | NA | NA | NA | (+) | NA | NA | NA |
| Paterson(13) | NA | WNL | WNL | WNL | NA | NA | NA | NA | WNL | NA | NA | NA |
| Rifino(14) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Rifino(14) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Sarma(15) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Sotoca(16) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Wong(18) | WNL | WNL | NA | WNL | NA | + | NA | NA | (+) | NA | NA | WNL |
| Zachariadis(19) | - | WNL | WNL | WNL | NA | NA | NA | NA | + | NA | NA | WNL |
| Zhao(20) | + | - | NA | - | NA | + | NA | NA | + | + | + | WNL |

Supplementary Table 2: Routine blood laboratory values. NA=not available; WNL=within normal limits; + = above normal limits; - = below normal limits; (+)=upper limit of normal or slightly above normal; WBC=white blood cell count; Hb=hemoglobin; ESR=erythrocyte sedimentation rate; ALAT=alanine transaminase; ASAT=aspartate transaminase; aPTT=activated partial thromboplastin time; CRP=C-reactive protein; PCT=procalcitonin; CK=creatinine kinase; \*same case reported in two publications. Reported values correspond to the timepoint closest to onset of neurological symptoms.

REFERENCES

1. Abdelhady M, Elsotouhy A, Vattoth S. Acute Flaccid Myelitis in COVID-19. BJR Case Rep. 2020;6(3):20200098.

2. AlKetbi R, AlNuaimi D, AlMulla M, AlTalai N, Samir M, Kumar N, et al. Acute myelitis as a neurological complication of Covid-19: A case report and MRI findings. Radiol Case Rep. 2020;15(9):1591-5.

3. Baghbanian SM, Namazi F. Post COVID-19 longitudinally extensive transverse myelitis (LETM)-a case report. Acta Neurol Belg. 2020.

4. Chakraborty U, Chandra A, Ray AK, Biswas P. COVID-19-associated acute transverse myelitis: a rare entity. BMJ Case Rep. 2020;13(8).

5. Chow CCN, Magnussen J, Ip J, Su Y. Acute transverse myelitis in COVID-19 infection. BMJ Case Rep. 2020;13(8).

6. Durrani M, Kucharski K, Smith Z, Fien S. Acute Transverse Myelitis Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Case Report. Clin Pract Cases Emerg Med. 2020;4(3):344-8.

7. Giorgianni A, Vinacci G, Agosti E, Cariddi LP, Mauri M, Baruzzi F, et al. Transient acute-onset tetraparesis in a COVID-19 patient. Spinal Cord. 2020;58(9):1042-4.

8. Kaur H, Mason JA, Bajracharya M, McGee J, Gunderson MD, Hart BL, et al. Transverse Myelitis in a Child With COVID-19. Pediatr Neurol. 2020;112:5-6.

9. Lisnic CN, V.; Hacina, E.; Topciu, G.; Manole, E.; Thurnher, M.M.; von Kummer, R. Acute transverse myelitis in a HIV-positive patient with COVID-19. Research Square. 2020.

10. Maideniuc C, Memon AB. Acute necrotizing myelitis and acute motor axonal neuropathy in a COVID-19 patient. J Neurol. 2020.

11. Masuccio FG, Barra M, Claudio G, Claudio S. A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection. J Neurol. 2020.

12. Munz M, Wessendorf S, Koretsis G, Tewald F, Baegi R, Kramer S, et al. Acute transverse myelitis after COVID-19 pneumonia. J Neurol. 2020;267(8):2196-7.

13. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020.

14. Rifino N, Censori B, Agazzi E, Alimonti D, Bonito V, Camera G, et al. Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy. J Neurol. 2020.

15. Sarma DB, L.A. A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection. Clin Pract Cases Emerg Med. 2020;4(3):321-3.

16. Sotoca J, Rodriguez-Alvarez Y. COVID-19-associated acute necrotizing myelitis. Neurol Neuroimmunol Neuroinflamm. 2020;7(5).

17. Valiuddin H, Skwirsk B, Paz-Arabo P. Acute transverse myelitis associated with SARS-CoV-2: A Case-Report. Brain Behav Immun Health. 2020;5:100091.

18. Wong PFC, S.; Newman, P.; Makan, A.: Srinivasan, K.; Crawford, E.; Dev, D.; Moudgil, H.; Ahmad, N. Lessons of the month 1: A case of rhombencephalitis as a rare complication of acute COVID-19 infection. Clinical Medicine (London). 2020;20(3):293-4.

19. Zachariadis A, Tulbu A, Strambo D, Dumoulin A, Di Virgilio G. Transverse myelitis related to COVID-19 infection. J Neurol. 2020.

20. Zhao KH, J.; Dai, D.; Feng, Y.; Liu, L.; Nie, S. Acute meylitis after SARS-CoV-2 infection: a case report. medRxiv. 2020.